- Home
- IMUX vs OPAD Comparison
IMUX vs OPAD Comparison
Compare IMUX & OPAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- OPAD
- Stock Information
- Founded
- IMUX 2016
- OPAD 2015
- Country
- IMUX United States
- OPAD United States
- Employees
- IMUX N/A
- OPAD N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- OPAD Real Estate
- Sector
- IMUX Health Care
- OPAD Finance
- Exchange
- IMUX Nasdaq
- OPAD Nasdaq
- Market Cap
- IMUX 110.8M
- OPAD 99.9M
- IPO Year
- IMUX N/A
- OPAD N/A
- Fundamental
- Price
- IMUX $1.06
- OPAD $3.73
- Analyst Decision
- IMUX Strong Buy
- OPAD Hold
- Analyst Count
- IMUX 5
- OPAD 5
- Target Price
- IMUX $13.20
- OPAD $5.33
- AVG Volume (30 Days)
- IMUX 1.5M
- OPAD 41.9K
- Earning Date
- IMUX 11-07-2024
- OPAD 11-04-2024
- Dividend Yield
- IMUX N/A
- OPAD N/A
- EPS Growth
- IMUX N/A
- OPAD N/A
- EPS
- IMUX N/A
- OPAD N/A
- Revenue
- IMUX N/A
- OPAD $985,005,000.00
- Revenue This Year
- IMUX N/A
- OPAD N/A
- Revenue Next Year
- IMUX N/A
- OPAD $37.39
- P/E Ratio
- IMUX N/A
- OPAD N/A
- Revenue Growth
- IMUX N/A
- OPAD N/A
- 52 Week Low
- IMUX $0.97
- OPAD $2.57
- 52 Week High
- IMUX $2.11
- OPAD $11.22
- Technical
- Relative Strength Index (RSI)
- IMUX 28.31
- OPAD 54.82
- Support Level
- IMUX $1.15
- OPAD $3.67
- Resistance Level
- IMUX $1.28
- OPAD $4.89
- Average True Range (ATR)
- IMUX 0.08
- OPAD 0.35
- MACD
- IMUX -0.01
- OPAD 0.10
- Stochastic Oscillator
- IMUX 12.90
- OPAD 42.72
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.